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ABSTRACT
An 8-year-old, spayed female, mixed breed dog diagnosed with hyperadrenocorticism and treated with 
trilostane for 13 days was presented to the clinic due to vomiting, shaking, and weakness. The ACTH stimulation 
test and electrolyte analysis confi rmed hypoadrenocorticism. Treatment with prednisolone and fl udrocortisone 
gave good results, however long lasting exogenous glucocorticoid administration led to a decrease in total 
and free thyroxine concentrations and caused clinical signs of hypothyroidism, such as lethargy and reduced 
appetite. The authors suspected euthyroid sick syndrome. After sixteen months therapy with prednisolone and 
fl udrocortisone ACTH stimulation tests still revealed low plasma cortisol concentrations in this dog, which 
suggested persistent hypoadrenocorticism. To the authors’ knowledge there have only been a few cases in which 
canine iatrogenic persistent hypoadrenocorticism or hypocortisolism was described after short term treatment 
with trilostane. However, in the previous cases the longest duration of hypocortisolism was 12 months.
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Introduction
Canine hypoadrenocorticism (Addison’s disease) is a disease resulting from the 
defi cient production and secretion of gluco- and/or mineralocorticoids by the adrenal 
glands. Two major forms of canine hypoadrenocorticism have been described: 
primary hypoadrenocorticism due to a lesion in the adrenal cortices, and secondary 
hypoadrenocorticism (hypocorticolism) due to insuffi cient production of ACTH by the 
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pituitary gland (GALAC et al., 2010). There are also forms of iatrogenic adrenocortical 
insuffi ciency caused by: prolonged glucocorticoid therapy leading to suppression of the 
hypothalamic-pituitary-adrenocortical axis or due to treatment with mitotane, which can 
cause necrosis of the zona fasciculata and zona reticularis in the adrenal glands (WILLARD 
et al., 1982; PLUMB, 2008a; GALAC et al., 2010).
Trilostane is an adrenal steroid synthesis inhibitor. It reduces synthesis of cortisol, 
aldosterone and adrenal androgens. Development of hypoadrenocorticism is one of 
the most serious adverse effects. Therefore, monitoring of therapy with trilostane is 
recommended (PLUMB, 2008b; KOOISTRA, 2010). The purpose of this case report is 
to show how important monitoring is in the treatment of hyperadrenocorticism with 
trilostane, and to show that even very brief therapy may lead to persistent Addison’s 
disease.
Case history 
History. An 8-year-old, 10 kg spayed female, mixed breed dog was presented to 
the Centre of Small Animal Health - Clinic Multiwet with a 4-week history of polyuria, 
polydipsia and was diagnosed with hyperadrenocorticism. Two weeks earlier an ACTH 
stimulation test was performed in another clinic. Hyperadrenocorticism was suspected 
due to the elevated ALP (1135 U/L). Diagnosis of hyperadrenocorticism was based on 
increased plasma cortisol concentrations (1379 nmol/L) 60 min after ACTH administration 
(reference interval for the test, 270 to 690 nmol/L). The referring veterinarian administered 
trilostane (Vetoryl®, Janssen Animal Health) at the initial dose of 2 mg/kg PO once a day 
for 10 days and then the dose was increased to 4 mg/kg daily in one dose. After 2 doses 
of 4 mg/kg the dog lost appetite. After the third higher dose of trilostane the owner of the 
dog observed clinical signs such as vomiting, shaking, and weakness.
Clinical exam fi ndings. At presentation at the Centre of Small Animal Health - 
Clinic Multiwet physical examination of the dog revealed heart rate, respiratory rate 
and temperature within reference intervals (112 beats/min, 38 breaths/min, and 37.9 
°C, respectively). The mucous membranes were dry and pale, and the skin turgor was 
decreased. The dog was estimated to be 5% dehydrated and suffering from abdominal 
pain.
Laboratory results. Initial diagnostic tests included a complete blood count (CBC), 
serum biochemical profi le, electrolyte analysis and ACTH stimulation test (tetracosactide 
0.25 mg/dog, IM, Synacthéne, Defi ante Farmaceutica). Results from the ACTH stimulation 
test and electrolyte analysis revealed decreased plasma cortisol concentrations: <27.6 
nmol/L 60 min after tetracosactide administration (reference interval for the test, 270 to 
690 nmol/L), hyponatremia (sodium 130.5 mmol/L; reference interval, 139.1 to 156.5 
mmol/L) and hyperkalemia (potassium 6.7 mmol/L; reference interval, 4.1 to 5.4 mmol/
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L). The sodium:potassium (Na:K) ratio was decreased at 19.5 (reference interval, 27 to 
40). Results from the CBC demonstrated leukocytosis (22.5 G/L; reference interval, 6.0 to 
14 G/L), neutrophilia with a left shift (segmented neutrophils count 18.45 G/L; reference 
interval, 2.9 to 12 G/L; non-segmented neutrophils count 1.8 G/L; reference interval, 
0.0 to 0.45 G/L), and mild anemia (red blood cell count 5.35 T/L; reference interval, 
5.5 to 8.0 T/L; hemoglobin concentration 7.9 mmol/L; reference interval, 7.45 to 11.17 
mmol/L; hematocrit 0.36 L/L; reference interval, 0.37 to 0.55). However, the severity of 
anemia might have been masked by hemoconcentration due to dehydration. On serum 
biochemical profi le, mild hypoglycemia (66 mg/dL; reference interval, 70 to 120 mg/dL), 
mild azotemia (creatinine 1.9 mg/dL; reference interval, 1.0 to 1.7 mg/dL; urea 112 mg/
dL; reference interval, 20 to 45 mg/dL), mildly elevated alkaline phosphatase (ALP 267 
U/L; reference interval, 20 to 155 U/L), moderately elevated alanine aminotransferase 
(ALT 222 U/L; reference interval, 3 to 50 U/L), and mildly elevated total serum protein 
concentration (76 g/L; reference interval, 55 to 70 g/L) were noted.
Diagnosis of iatrogenic hypoadrenocorticism was based on the results of the ACTH 
stimulation test, electrolyte analysis and decreased Na:K ratio. 
Therapy. For the initial treatment, a single dose of dexamethasone (Dexasone, ScanVet 
Poland), 0.5 mg/kg, IV; buprenorphine (Bunondol, Warszawskie Zakłady Farmaceutyczne 
Polfa), 10 μg/kg, IV; metoclopramide (Metoclopramidum, Polpharma), 0.25mg/kg, SC, 
q6h; 0.9% saline (Natrium Chloratum 0,9%; Polfa Lublin), 15 mL/kg, IV, q6h; and 5% 
glucose (Injectio Glucosi 5%, Polfa Płyny), 15 mL/kg, IV, q 6h, were administered the 
fi rst day. Fluid therapy was continued for 3 days, and antiemetic and analgesic therapy for 
1 day. Concurrently the dog had been given fl udrocortisone (Cortineff, Polfa Pabianice), 
0.01 mg/kg, PO, q12h for 3 days, and prednisolone (Encortolon, Polfa Pabianice), 0.5 
mg/kg, PO, q24h for 2 days. 
After 3 days of therapy, the dog’s heart rate, respiratory rate, and temperature 
were within reference intervals. The dog ate spontaneously and had normal vital signs. 
Biochemistry revealed hyponatremia (sodium 133.7 mmol/L; reference interval, 139.1 to 
156.5 mmol/L) and normokalemia (potassium 5.0 mmol/L; reference interval, 4.1 to 5.4 
mmol/L). However, the Na:K ratio was still mildly decreased at 26.7 (reference interval, 
27 to 40). The dog had still leukocytosis (24.0 G/L), mild anemia, and increased ALP and 
ALT activity. Glucose, creatinine and urea concentrations were within reference intervals. 
The patient was discharged after 3 days of hospitalization. Fludrocortisone (Cortineff, 
Polfa Pabianice), 0.01 mg/kg, PO, q12h for 7 days and prednisolone (Encortolon, 
Polfa Pabianice), 0.5 mg/kg, PO, q24h for 7 days were prescribed for treatment of the 
hypoadrenocorticism, and amoxicillin with clavulanic acid (Synulox, Pfi zer) 12.5 mg/kg, 
PO, q12h, for 7 days because of leukocytosis. 
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After a week the dog was in a good condition. Biochemistry revealed mild 
hyponatremia (sodium 138.6 mmol/L), hyperkalemia (potassium 6.1 mmol/L), decreased 
Na:K ratio (22.7), normoglycemia, mild leukocytosis (15.5 G/L) and mild anemia (red 
blood cell count 5.4 T/L; hemoglobin concentration 7.9 mmol/L; hematocrit 0.35 L/L). 
Fludrocortisone and prednisolone were continued for next 7 days, and after that time, 
sodium and potassium concentration were within reference intervals (sodium 141.6 
mmol/L; potassium 5.3 mmol/L). However Na:K ratio was still mildly decreased (26.7).
Fig. 1. Sodium and potassium concentration (mmol/L) measured in the serum of the dog 
once a month between May 2008 and January 2009 (Na, sodium concentration; K, potassium 
concentration; Na:K, sodium: potassium ratio)
Fludrocortisone therapy (Cortineff, Polfa Pabianice), 0.01 mg/kg, PO, q12h and 
prednisolone therapy (Encortolon, Polfa Pabianice), 0.5 mg/kg, PO, q24h, were continued 
for the next 9 months. Sodium and potassium concentrations were measured once a month 
(Fig. 1). After this period an ACTH stimulation test was performed again. Results from the 
test revealed low plasma cortisol concentration (81 nmol/L) 60 min after tetracosactide 
administration (Synacthéne, Defi ante Farmaceutica). A diagnosis of persistent stable 
hypoadrenocorticism was made. Fludrocortisone and prednisolone therapies were still 
continued for the next 5 months, and sodium and potassium concentrations were measured 
once every 2 months. The Na:K ratio, sodium and potassium concentrations were within 
reference intervals and the dog was in good condition.
The owner of the dog observed lethargy and reduced appetite in the dog. Clinical 
examination did not reveal any abnormalities. Diagnostic tests included a CBC, serum 
biochemical profi le, electrolyte analysis, ACTH stimulation test, and abdominal ultrasound 
examination. The laboratory tests revealed only low plasma cortisol concentration after 
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tetracosactide administration (Synacthéne, Defi ante Farmaceutica). The Na:K ratio, 
sodium and potassium concentration were within the reference interval. Biochemical 
and CBC tests did not reveal any abnormalities. Abdominal ultrasonography revealed 
hepatomegaly and small, hyperechoic adrenal glands (diameter 2.8 mm). Tests for levels 
of total thyroxine (tT4), free thyroxine (fT4) were performed and revealed a decrease 
in tT4 and fT4 concentrations (tT4, 8.1 ng/mL; reference interval, 15 to 40 ng/mL; fT4, 
0.87 ng/dL; reference interval, 1 to 4 ng/dL). A suspicion of euthyroid sick syndrome as 
a result of glucocorticoid therapy was made.
ACTH stimulation test was performed four weeks later and revealed low plasma 
cortisol concentration (96 nmol/L) 60 min after tetracosactide administration. 
Discussion
There have been a few cases in which canine iatrogenic persistent hypoadrenocorticism 
or hypocortisolism were described after short term treatment with trilostane (CHAPMAN 
et al., 2004; RAMSEY et al., 2008). REUSCH et al. (2007) showed that dogs with 
hyperadrenocorticism treated with trilostane had variable degrees of adrenal necrosis. 
Also CHAPMAN et al. (2004) showed that trilostane therapy may lead to adrenal cortical 
necrosis. The mechanism of cell death in the adrenal glands after treatment with trilostane 
is unknown. REUSCH et al. (2007) hypothesized that trilostane or its metabolites may lead 
directly to necrosis and/or apoptosis. These authors suggested that in some dogs necrosis 
or apoptosis in the adrenal cortex may lead to adrenal insuffi ciency. Hypoadrenocorticism, 
as the result of cell death in the adrenal glands, may be observed in dogs treated with 
trilostane for a period longer than 15 months with mean trilostane dosage higher than 11.7 
mg/kg daily and with a history of therapy with mitotane before treatment with trilostane. 
However, in this case report the dog was treated only 13 days with a lower dosage of 
trilostane and had not been treated with mitotane earlier. CHAPMAN et al. (2004) also 
observed clinical signs of hypoadrenocorticism and marked necrosis in the adrenal glands 
in a dog after trilostane therapy lasting only 22 days with a dosage 7.1 mg/kg daily. 
Moreover, that dog had not been treated with mitotane before the therapy with trilostane 
as well. A similar case report was described by RAMSEY et al. (2008). These authors 
observed clinical signs of hypoadrenocorticism after 3-day therapy with trilostane at a 
dose of 5 mg/kg daily. That dog had also not been treated with mitotane. Thus, it seems 
probable that even short-term trilostane therapy may lead to adrenal necrosis caused by 
direct action of trilostane or its metabolites. Yet, both CHAPMAN et al. (2004) and REUSCH 
et al. (2007) did not exclude an idiosyncratic reaction to the drug. The dog described in 
this case report was treated with trilostane for a very short period and developed clinical 
signs of adrenal insuffi ciency. It seems probable that this dog also had necrotic lesions 
in the adrenal glands after treatment with trilostane and these lesions might have led 
to hypoadrenocorticism. However, the owner of the dog eventually did not consent to 
biopsy of the adrenal glands. 
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The therapy with fl udrocortisone and prednisolone allowed glucose, sodium and 
potassium levels to normalize. Clinical signs of hypoadrenocorticism also ceased after 
this therapy. However, probably the exogenous glucocorticoid administration caused 
euthyroid sick syndrome. This supposition may be confi rmed by the results of the tests 
for levels of tT4 and fT4 (FELDMAN and NELSON, 2004). 
Trilostane therapy seems to be a safer therapy than mitotane for canine 
hyperadrenocorticism. CLEMENTE et al. (2007) showed that dogs treated with trilostane 
tended to live longer than dogs treated with mitotane. In most dogs the drug is well 
tolerated. NEIGER et al. (2002) observed clinical signs of hypoadrenocorticism in 
only 2 out of 78 dogs treated with trilostane. Moreover, in one of these dogs signs of 
hypoadrenocorticism quickly resolved after the withdrawal of the drug. In the previous 
case report RAMSEY et al. (2008) described a dog with hypocortisolism after 3 doses 
of trilostane. In that case hypocortisolism persisted and progressed for more than 3 
months despite immediate withdrawal of the trilostane. After prednisolone therapy the 
clinical signs of hypocortisolism resolved. However, that dog had sodium and potassium 
concentrations within reference intervals. Thus the dog had isolated hypocortisolism. In 
that dog prednisolone therapy was required for more than 1 year. However, in this case 
prednisolone had to be combined with fl udrocortisone owing to the abnormal sodium 
and potassium concentrations and decreased Na:K ratio. Moreover, the therapy was 
continued for 16 months, and ACTH stimulation tests still revealed low plasma cortisol 
concentration, which suggested persistent hypoadrenocorticism. This case showed how 
important it is to monitor the treatment of hyperadrenocorticism with trilostane and also 
that even very brief therapy may lead to persistent Addison’s disease probably caused by 
irreversible lesions in the adrenal glands.
KOOISTRA (2010) recommended initial treatment with trilostane at a dose of 2 mg/kg 
daily in one or two portions and adjusting the dose according to the clinical response and 
result of ACTH stimulation test performed 2 weeks after the start of the therapy. These 
recommendations are very good, however, according to the authors of this case report, it 
should be emphasized that ACTH stimulation test should be performed every time before 
increasing the dose of the drug. Moreover, it seems that administration of trilostane in two 
portions daily may be safer than in one portion. 
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SAŽETAK
Kastrirana kuja, mješanka, u dobi od osam godina, s prethodno dijagnosticiranim hiperadrenokorticizmom, 
liječena trilostanom 13 dana, bila je dovedena na kliniku zbog povraćanja, drhtanja i slabosti. Podražaj 
ACTH-om i analiza elektrolita potvrdili su da je riječ o hipoadrenokorticizmu. Liječenje prednizolonom i 
fl udrokortizonom dalo je dobre rezultate. Ipak dugotrajno davanje egzogenog glukokortikoida dovelo je do 
smanjenja koncentracije ukupnog i slobodnog tiroksina te je uzrokovalo kliničke znakove hipotiroidizma 
kao što su letargija i smanjeni apetit. Autori su posumnjali na eutiroidni sindrom. Nakon 16 mjeseci terapije 
prednizolonom i fl udrokortizonom, ACTH podražajni testovi pokazivali su još uvijek nisku koncentraciju 
kortizola u plazmi te kuje što je upućivalo na perzistentni hipoadrenokorticizam. Dosada je opisano svega 
nekoliko slučajeva jatrogenoga perzistentnoga hipoadrenokorticizma ili hipokortizolizma nakon kratkotrajne 
primjene alostana. U prijašnjim slučajevima hipokortizolizam je najduže trajao 12 mjeseci.
Ključne riječi: Adisonova bolest, pas, jatrogeni hipoadrenokorticizam, trilostan
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